La Jolla Institute for Immunology
La Jolla Institute for Immunology was established in 1988 by a coalition of leaders from academia and industry, including Dr. Makoto Nonaka, the Institute’s founding president, and Dr. Kimishige Ishizaka, the Institute’s first scientific director. These leaders envisioned a unique and dynamic partnership between basic science and applied research, one that would lead to breakthroughs in the understanding of the immune system and improve human health through the development of treatments and cures for immune system disorders.
Content by La Jolla Institute for Immunology
|3 min read
New Discovery Paves the Way for Antivirals Against Ebola Virus and Its Deadly Relatives
Scientists capture first look at key viral structure within infected host cells
|5 min read
Latest Study Dives Deeper into T-Cell Activation and Response
How do T-cell receptors on the cell surface alert the nucleus far inside the cell of trouble?
|4 min read
Scientists Confirm Smallpox Vaccine Also Teaches T Cells to Fight Mpox
First study to provide evidence that the JYNNEOS vaccine induces a T cell response that recognizes mpox
|3 min read
Immunologic Defect May Leave Some Vulnerable to Rare Bacterial Infection
Scientists uncover defect that stops T cells from fighting MAC bacteria
|2 min read
How Human Cells Become Zika Virus Factories
Scientists uncover major clue toward developing a pan-flavivirus therapy
|3 min read
New Vaccine Ingredient Shows Promise
Most vaccines include particles called adjuvants. But not all adjuvants are created equal
|3 min read
T Cells Mount Attacks against Many SARS-CoV-2 Targets—Including New Variant
By attacking the virus from many angles, T cells have the tools to recognize different SARS-CoV-2 variants
|3 min read
A Closer Look at T Cells Reveals Differences in Mild vs Severe COVID-19
The new research highlights the enormous variability in how T cells respond to the deadly virus
|3 min read
Can Exposure to Other Coronaviruses Help Us Fight COVID-19?
Researchers caution: It is too soon to say whether pre-existing immune cell memory affects COVID-19 clinical outcomesPage 1 of 1
